Insider · CIK 0002005916
Darcy Mootz
Files at ELEV (Elevation Oncology, Inc.). First filing -, latest -.
Darcy Mootz files SEC Form 4 as director at ELEV (Elevation Oncology, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Darcy Mootz has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 23, 2025 | ELEV Elevation Oncology, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -55,000 | $0.00 | $0 | 0 | Jul 24, 2025 |
| Jul 23, 2025 | ELEV Elevation Oncology, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Jul 24, 2025 |
| Jul 23, 2025 | ELEV Elevation Oncology, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Jul 24, 2025 |
| Jun 5, 2025 | ELEV Elevation Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Jun 9, 2025 |
Questions about Darcy Mootz
Answered from the filings on this page, as of the latest one.
Is Darcy Mootz buying or selling?
Darcy Mootz has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Darcy Mootz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Darcy Mootz has 0.
Where does Darcy Mootz file Form 4?
Darcy Mootz has filed Form 4 at ELEV (Elevation Oncology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.